Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model

在特发性多中心Castleman病患者中，与利妥昔单抗疗法相比，司妥昔单抗单药治疗可改善无进展生存期；采用单臂荟萃分析方法和广义线性混合模型对研究进行间接比较